Omnigen Biotechnologies

Omnigen is a regenerative medicine company specializing in the development of biological products derived from human amniotic membrane. The company's proprietary technology allows for the dry-preservation of amniotic tissue, maintaining its structural and biochemical properties while enabling room-temperature storage and immediate clinical use. Its flagship product, Omnigen, is widely used in ophthalmology to treat complex ocular surface conditions and in wound care for chronic and acute injuries. Omnigen also offers OmniLenz, a specialized delivery system that allows the amniotic membrane to be applied to the eye in an outpatient setting without the need for surgery. Based in the UK as a spin-out from the University of Nottingham, the company focuses on providing stable, easy-to-use regenerative solutions for clinical practice.